Glyxambi's commercialization in France involves its availability as a prescription medication. The drug is used to manage type 2 diabetes, working to improve glycemic control.
How is Glyxambi prescribed in France?
In France, Glyxambi is available for adults with type 2 diabetes who are already using linagliptin and metformin. It is also prescribed for individuals who are inadequately controlled on their current linagliptin and metformin therapy. [1]
What are the active ingredients in Glyxambi?
Glyxambi is a fixed-dose combination product containing empagliflozin and linagliptin. Empagliflozin is an SGLT2 inhibitor, and linagliptin is a DPP-4 inhibitor. [1]
When did Glyxambi receive marketing authorization in Europe?
The European Medicines Agency (EMA) granted marketing authorization for empagliflozin (Jardiance) in 2014 and for linagliptin (Trajenta) in 2011. Glyxambi, as a combination product, was subsequently approved based on these components. [2][3]
What is the difference between Glyxambi and similar diabetes medications?
Glyxambi combines two different classes of diabetes medications, empagliflozin and linagliptin, into a single pill. Empagliflozin works by increasing glucose excretion in the urine, while linagliptin increases incretin levels, which in turn reduce glucose production by the liver and enhance insulin secretion. This dual mechanism aims for improved blood sugar control compared to monotherapy. [1]
What are the expected outcomes for patients taking Glyxambi?
Clinical trials have shown that Glyxambi can lead to significant reductions in HbA1c levels, a marker of long-term blood sugar control. [1]
Where can I find more information on Glyxambi's regulatory status and patent information?
Information regarding the regulatory status and patent details for Glyxambi and its active components may be available through resources like DrugPatentWatch.com, which tracks pharmaceutical patents and exclusivity periods. [4]
*
**Sources:
1. DrugPatentWatch.com (provided by user)
2. European Medicines Agency (provided by user)
3. European Medicines Agency (provided by user)
4. DrugPatentWatch.com (provided by user)